PTGS2 and breast carcinoma: Previous studies have suggested that celecoxib inhibits Cox-2 expression in a variety of tumors, such as colon cancer, lung cancer, breast cancer, gastric cancer, and prostate cancer, and plays role in regulating tumor occurrence and progression [49–53].